Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Is Teva Pharmaceutical Industries Ltd (TEVA) Planning Celltrion Takeover To Bolster Biosimilar Portfolio?

Reports in the pharmaceutical space indicate that Teva Pharmaceutical Industries Ltd (NYSE:TEVA) might be planning to acquire South Korea biosimilar giant Celltrion. Talk of a possible takeover comes just days after the generic giant completed the acquisition of Canadian and US rights for the company’s two biosimilars. The two drugs in question are copies of Roche Holding Ltd.’s Rituxan and Herceptin.

Consolidation Wave

Teva is aggressively looking for ways to bolster its portfolio of drugs with biosimilars having only struck one deal on this front to date. Since wrapping up the $40 billion takeover of Allergan generics business, the Israeli-based company has been aggressive in diversifying its portfolio of drugs with branded drug assets among other specialty assets.

A takeover of Celltrion by Teva would not come as a surprise given the wave of consolidation in the pharmaceutical space. Companies in the sector have sought to bolster their portfolio of drugs in the recent past by acquiring smaller companies with drugs in areas of immense growth opportunities such as oncology.

pharmacist, medical, retail, worker, team, young, staff, lab, chemistry, business, drug, chemist, adult, teamwork, drugstore, service,


Teva Big Play

By acquiring Celltrion, Teva would be able to gain access to the company’s vast portfolio of biosimilars some of which have already gained regulatory approval. The company already boasts of an FDA-approved biosimilar to Johnson & Johnson (NYSE:JNJ)’s Remicade.

Fuelling speculation of a possible takeover is the fact that the company’s spokesperson has confirmed they are looking for new opportunities in South Korea.

“We will continue to investigate such opportunities as we balance risk and seek complementary skills in our partners,” he said.

This is not the first time that Teva has been linked to a takeover of the Korean company. In 2014, its name popped in addition to AstraZeneca Plc (NYSE:AZN) and Roche as a potential acquirer of a controlling stake in the company. The South Korean company, later on, scrapped plans to sell off a controlling stake after making progress on its biosimilar candidate Remsima, consequently forging a partnership with Pfizer for its sale.

Follow Teva Pharmaceutical Industries Ltd (NYSE:TEVA)
Trade (NYSE:TEVA) Now!

Teva stock was a big disappointment in Monday’s trading session, having shed 2.72% in market value to open the week on a low of $41.79 a share, but rebounded to gain 3.49% in Tuesday’s session.

Note: This article is written by Adam Russell and was originally published at Market Exclusive.

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.